Dimerix
Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred pharmaceutical products for global markets. Their focus is on identifying and developing drugs for areas with unmet needs, particularly in inflammatory diseases affecting the kidney and lungs.
Short position
Dimerix (ASX:DXB) has 0.05% of its shares on issue reported as short positions as of 22 Sept 2026, or about 270,986 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.50% in March 2025. DXB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Dimerix (DXB) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $4.4Mvs $5.6M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- NPAT
- −$29.8Mvs −$13.3M (FY25)
- Yahoo Finance, as at 29 Sep 2026
- EPS (diluted)
- −$0.050T (source: Derived: trailing 12 months at year end)vs −$0.024 (FY25)
- Derived: trailing 12 months at year end, as at 29 Sep 2026
- Rev YoY
- −22.1%FY
- EPS YoY
- n/aTTM
- Derived: trailing 12 months at year end
Key ratios
Year to 30 Jun 2026 (FY); balance sheet at 30 Jun 2026; prices to 9 Oct 2026
- Gross margin
- 100.0%
- Operating margin
- −854.6%
- Net margin
- −685.3%
- FCF margin
- −1,191.0%
- ROE
- n/a
- ROA
- −39.8%
- FCF conversion
- n/a
- Net cash (excl. leases)
- $16.2M
- Net debt / EBITDA
- n/a
- Current ratio
- 3.8×
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- $132.1M
- P/E
- n/a
- P/B
- n/a
Ratios use the reporting currency (AUD); market cap is in AUD. Source: Yahoo Finance, as at 29 Sep 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $4.4M | $5.6M | $407.5K | n/a |
| Gross profit | $4.4M | $5.6M | $407.5K | n/a |
| Operating income | −$37.2M | −$32.0M | −$25.2M | −$22.8M |
| EBITDA | −$37.0M | −$31.9M | −$25.2M | −$22.8M |
| EBIT | −$37.2M | −$32.0M | −$25.2M | −$22.8M |
| Pretax income | −$34.6M | −$31.7M | −$17.1M | −$13.8M |
| Tax | −$4.7M | −$18.4M | $0 | $0 |
| NPAT | −$29.8M | −$13.3M | −$17.1M | −$13.8M |
| Net interest income | $623.9K | $327.0K | $176.0K | $36.8K |
| EPS basic | −$0.050T (source: Derived: trailing 12 months at year end) | −$0.024 | −$0.038 | −$0.042 |
| EPS diluted | −$0.050T (source: Derived: trailing 12 months at year end) | −$0.024 | −$0.038 | −$0.042 |
| Shares | 600.4M | 598.5M | 550.2M | 388.1M |
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and 2026 Annual ReportAnnual Results27 Aug 2026via asx_announcements
- Dimerix Quarterly Activities Report and Appendix 4CQuarterly Report30 Jul 2026via asx_announcements
- Dimerix Quarterly Activities Report and Appendix 4CQuarterly Report30 Apr 2026via asx_announcements
- Appendix 4D and Half Year Financial ReportHalf Year Results26 Feb 2026via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report29 Jan 2026via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report29 Oct 2025via asx_announcements
- Appendix 4E and 2025 Annual ReportAnnual Results28 Aug 2025via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report25 Jul 2025via asx_announcements
- Quarterly Appendix 4C and Activities ReportQuarterly Report30 Apr 2025via asx_announcements
- Half-Year Financial Report & Appendix 4D - 31 December 2024Half Year Results25 Feb 2025via asx_announcements
Showing 10 of 18 reports